Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Videos
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Shop
  • Events
  • Contact us

2012 prostate colloquium

“Standards in reporting of MRI targeted prostate biopsies (START): recommendations from an international working party”

In October 2012 23 leading radiologists, urologists, histopathologists and methodologists gathered in New York to attend a consensus meeting organised by Pelican Cancer Foundation and the Peter Michael Foundation. Their aim was to define the standards required for the reporting of studies of MRI-targeted prostate biopsies. A previous review had identified a number of areas of incomplete reporting in studies in this area, and it was appropriate to set out a set of minimum standards for reporting of such studies in the future.

They took part in a study involving a pre-meeting questionnaire and a discussion of the results at the meeting. In this way they could reach a consensus on what the START (STAndards of Reporting for mri-Targeted biopsy studies) checklist should include.

This checklist will improve the quality of reporting and facilitate a comparison between a systematic biopsy approach and an MRI-targeted approach. Collation of data from studies fulfilling the START criteria may more easily allow the evaluation of MRI-targeted biopsy as a diagnostic strategy for the selective detection of clinically significant cancer.

Link to final report on PubMed. This was awarded the Best Paper in Urological Oncology at the ’11th Meeting of the EAU Section of Oncological Urology’.

Pelican Cancer FoundationFollow

Driving innovation and advancing surgery to help patients live well, for longer.

Pelican Cancer Foundation
lapcoleadmarkMark Coleman FRCS MD@lapcoleadmark·
14h

Join us on this evidence based course to improve the skills of trainers and aspiring trainers! Now rolling out in centres globally! https://twitter.com/ICENICentre/status/1526559748602085377

Reply on Twitter 1526568932097785858Retweet on Twitter 15265689320977858581Like on Twitter 15265689320977858581Twitter 1526568932097785858
ACPGBI@ACPGBI@ACPGBI·
16 May

Most delighted that @Brendan92855812 past @ACPGBI President will join us to deliver the 2022 Hunterian Lecture at #ACGBI2022 in Edinburgh on Mon 4 Jul at 17:30. Chaired by @ACPGBI President @petesagar7
▶️https://bit.ly/ACPGBI22-4-Jul

Reply on Twitter 1526171048491745280Retweet on Twitter 15261710484917452809Like on Twitter 152617104849174528014Twitter 1526171048491745280
ChrisGBoultonChris Boulton@ChrisGBoulton·
12 May

Today's taster of my Big Mountains Exhibition at the @westridgestudio Highclere on 21/22 May is my triptych of the Monte Rosa Massif. #oswbnh2022 #westridgestudio #artexibition #openstudios #bigmountains #alpsmountains #monterosa #pelicancancerfoundation #mycancermychoices

Reply on Twitter 1524787378711404545Retweet on Twitter 15247873787114045451Like on Twitter 15247873787114045451Twitter 1524787378711404545
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2022 · Outreach Pro Theme on Genesis Framework · WordPress · Log in